29
Participants
Start Date
January 31, 2014
Primary Completion Date
November 9, 2016
Study Completion Date
November 9, 2016
MLN7243
"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
Boston
St Louis
Cleveland
Philadelphia
Charleston
Nashville
San Antonio
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY